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ABSTRACT  
          Aqueous solubility is a limiting factor in the oral 
bioavailability of a certain class of poorly water soluble drugs. A 
consequence of low aqueous solubility is a slow dissolution rate. 
For the drugs with low aqueous solubility and high permeability 
the dissolution rate will be the rate limiting step for absorption. 
The most successful techniques that are employed for dissolution 
enhancement are micronization, formulation of amorphous 
systems and cyclodextrins containing dosage forms. This 
combined approaches to improve the dissolution of some poorly 
soluble drugs. Micronization increases the dissolution rate of 
drugs through increased surface area. The high surface area of 
drug micro/nano particles renders them thermodynamically 
unstable, promoting agglomeration and crystal growth. 
Microparticles of the poorly water soluble drugs were produced 
by the supercritical antisolvent method and simultaneously 
mixed with pharmaceutical excipients in a single step to prevent 
the drug agglomeration of drug particles. In the third approach 
cyclodextrins (CDs) were used as pharmaceutical solubilizers and 
inclusion complexes of drugs with β-CD.  
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INTRODUCTION  
Poor aqueous solubility of drugs is an 
industry wide issue for pharmaceutical 
scientists. Because of their low aqueous 
solubility, up to 40% of new chemical entities 
fail to reach market despite exhibiting potential 
pharmacodynamic activities (Lipinski 2005). In 
addition, up to 50% of orally administered 
drugs suffer from formulation problems related 
to their high lipophilicity (Gursoy and Benita 
2004). Poorly aqueous soluble drugs are 
associated with slow drug absorption leading 
eventually to inadequate and variable 
bioavailability (Amidon et al., 1995; Leuner and 
Dressman, 2000). Oral absorption of a drug 
can be influenced by variety of factors, such as 
the physicochemical properties (e.g., pKa, 
solubility, stability, diffusivity, lipophilicity, 
polar-nonpolar surface area, presence of 
hydrogen bond functionalities, particle size and 
crystal form), physiological conditions (e.g., 
gastrointestinal pH, blood flow, gastric 
emptying, small intestinal transit time, colonic 
transit time and absorption mechanisms) and 
type of dosage form (e.g., tablet, capsule, 
solution, suspension and emulsion). Despite 
this complexity, the work revealed that 
permeability of drug through the gastro-
intestinal (GI) membrane and solubility/ 
dissolution of drug dose in the GI environment 
are the fundamental events in successful drug 
absorption (Dahan et al., 2009). The 
Biopharmaceutics Classification System (BCS) 
classifies drugs into four categories (Table I) 
based on their solubility and permeability 
characteristics. According to BCS, the oral 
bioavailability of class-II (poorly soluble and 
highly permeable) drugs is limited by their 
solubility and dissolution rate (Yu et al.,  2002).  
 















If the ratio of the drug dose to the 
lowest drug saturation solubility in the pH 
range of 1-8 is greater than 250 then the drug is 
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called poorly soluble. So regardless of other 
factors, it is reasonable to conclude that a 
compound must be in solution form or 
solubilized in the GI tract to diffuse into and 
across the enterocytes lining the intestinal 
lumen for absorption (Gullapalli, 2001). The 
complete oral absorption of a drug depends on 
the events depicted in Equation 1, their 
importance relative to one another and the rate 
at which they occur (Dressman and Reppas, 
2000). Drug release (dissolution) and 
absorption must occur within the available 
transit time i.e., the time the drug spends in GI 
tract and at the site of absorption. The 
dissolution rate of the drug is given by the 




Where A is the surface area of the drug; 
D is the diffusion coefficient of the drug; h is 
the effective boundary layer thickness; Cs is the 
saturation concentration of the drug under the 
local GI conditions; V is the volume of the 
fluid available to dissolve the drug, and Xd is 
the amount of drug already dissolved.  
The diffusion coefficient (D) and 
diffusion layer thickness (h) are less suitable 
targets for dissolution rate enhancement/ 
bioavailability optimization. D depends on the 
molecular weight of the drug and the viscosity 
of the gastro intestinal fluids, which varies in 
the fed and fasted state and is subject to large 
intra- and inter-subject variability. h also largely 
depends on the hydrodynamics during GI 
transit. Therefore, based on the equation 1, the 
possibilities for increasing the dissolution/ 
bioavailability are to increase the effective 
surface area or to improve the apparent 
solubility of the drug. Different approaches to 
enhance the dissolution rate of poorly soluble 
drugs include, but are not limited to, particle 
size reduction (Rasenack and Mueller, 2002; 
Jounela et al., 1985; Liversidge and Cundy, 
1995; Vogt et al.,  2008), inclusion complexation 
with cyclodextrins (Brewster, et al., 1992; Badr-
Eldin, et al., 2008; Sathigari et al., 2009),solid 
dispersion (Joshi et al.,  2004; Dannenfelser, et 
al.,  2004; Kennedy et al., 2008), salt formation 
(Han, et al., 2007; O'Connor and Corrigan, 
2001), use of surfactants (Balakrishnan et al., 
2004; Chiou, et al.,  1976), cosolvency 
(Kawakami et al., 2004; Viernstein et al.,  2003), 
and various particle engineering techniques 
(Blagden, et al., 2007; Jung and Perrut, 2001; 
Loth and Hemgesberg, 1986). Among, the 
different approaches, they are the most 
successful technologies in terms of the number 
of commercial products which are on the 
market (Tables II, III and IV).  
 
Micro/Nano particle production  
This is one of the most efficient and 
reliable methods used commercially to improve 
the bioavailability of poorly soluble drugs         
that is limited by poor dissolution rates 
(Jonghwi, 2003). Improvement in bioav-
ailability  after micronization of drugs has been                 
well documented for numerous drugs (Farinha, 
et al., 2000). Micronization increases the 
dissolution rate of drugs through increased 
surface area (Barrett, et al., 2008). Reduction of 
the particle size to micron or nano size can be 
achieved by precipitation from a solution (built-
up) or milling (sized–down). Milling is a well 
established technique which is relatively cheap, 
fast and is easy to scale-up, but it has several 
disadvantages (Wong, et al.,  2006). This method 
has limited opportunity to control the final 
particle size, shape, morphology, surface 
properties and electrostatic charge and it is 
difficult to reduce the particle size below 1 μm 
because of the cohesiveness of the particles. In 
addition, milling is a high energy process which 
causes disruptions in the drugs crystal lattice, 
resulting in the presence of disordered                  
or amorphous regions in the final product 
(Saleki-Gerhardt, et al., 1996). Wet milling 
techniques (bead milling and high pressure 
homogenization) can produce submicron 
particles without any concern for particle 
cohesiveness. However, these techniques often 
require a long time, introduce impurities, can 
also cause disruptions in the drug crystal lattice, 
and limits flexibility in controlling particle 
morphology. These methods also require 
further pharmaceutical operations such as 
lyophilization or spray drying to produce solids 
for use in oral solid dosage forms. Supercritical 
fluids are involved in numerous industrial 
processes and offer considerable advantages          
as solvents or anti solvents for crystallization 
and   precipitation  processes (Matteucci, 2006).  
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Among different methods using 
supercritical fluids, precipitation using 
supercritical carbon dioxide (CO2) as an 
antisolvent is well known and has been used to 
micronize several kinds of compounds (Jung 
and Perrut, 2001). Carbon dioxide is an ideal 
supercritical fluid because of its low critical 
temperature (31.18oC) and pressure (73.8 Pa), 
low cost, non-toxicity and inert nature. In 
addition, CO2 is recyclable and environmentally 
safe (Rogers, et al.,  2004). The driving force for 
particle formation using supercritical fluids is 
super saturation which is same as that of 
traditional crystallization. In the supercritical 
anti-solvent process the solubilization power of 
a solvent is decreased by addition of a 
supercritical fluid as an antisolvent in which the  
solute is insoluble (Figure 1). The 
nucleation and consequent growth of the 
crystals from the solute-organic solvent-
antisolvent are governed by the diffusion of the 
antisolvent into the organic phase and the 
evaporation of the organic solvent into the 
antisolvent phase (Reverchon and Della 2001). 
The rapid diffusion of antisolvent into the 
organic solvent produces the supersaturation of 
the solute that leads to nucleation and particle 
formation. 
 
Complexation with Cyclodextrins  
Cyclodextrins (CDs) have been used 
extensively in pharmaceutical research and 
development, and there are currently over 30 
marketed cyclodextrins containing pharma-
ceutical products world wide (Pasquali, et al., 
2008). Some of the cyclodextrins based 
marketed products world wide are given in 
Table IV (Lengsfeld, et al., 2000). Most 
commonly, CDs are used in drug formulations 
as solubility enhancers because of their ability 
to form water soluble inclusion complexes with 
poorly  soluble  drugs.  The    complexation  with  
Table II. List of nano/ micro particle based drugs that are commercialized 
 
Description Drug Technology Brand name Company 
Downsizing     

























2.Homogenization Fenofibrate IDD™ Triglide® Skyepharma 
 
Table III. Commercially available solid dispersion  
 
Drug Brand name Company 
Griseofulvin Gris-PEG® Pedinol Pharmcal Inc. 
Nabilone Cesamet® Valent Pharmaceutical 
Lopinavir,Ritonavir Kaletra® Abbot 
Itraconazole Sporanox® Janseen pharmaceutical 
Etravirin Intelence® Tibotec 
Everolimus Certican® Novartis 
Verapamil Isoptin SR-E® Abbott 
Nivaldipine Nivadil® Fujisawa Pharmaceutical Co.Ltd. 
Tacrolimus Prograf® Fujisawa Pharmaceutical Co.Ltd. 
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CDs enhances the solubility, dissolution rate, 
and bioavailability of poorly soluble drugs. In 
addition, CDs are used to enhance stability, to 
mask drug taste, to aid pharmaceutical 
processes by serving as filler, binder and 
channeling agents, etc., and as an osmogen in 
controlled release osmotic pump dosage forms. 
CDs are cyclic (α-1,4)-linked oligosaccharides 
of α-D-glucopyranose containing a relatively 
hydrophobic central cavity and hydrophilic 
outer surface. The central cavity provides a 
lipophillic microenvironment into which 
suitably sized lipophilic drug molecules can be 
accommodated due to hydrophobic 
interactions. No covalent bonds are formed         
in the drug/cyclodextrin (CD) complexation  
and   the  complexes     are   readily   dissociated. 
The three natural CDs are α-CD, β-CD, and γ-
CD which are made up of 6, 7 or 8 
glucopyranose units respectively. Several 
chemically modified CD derivatives have been 
reported in the literature to enhance the 
Table IV. List of marketed pharmaceutical containing cyclodextrins 
 
Drug Brand name Company Formulation 
αcyclodextrin(αCD)    
Cefotiam-hexetil HCL Pansporin Takeda Tablet 
OP-1206 Opalmon Ono Tablet 
βCyclodextrin(βCD)    
Benexate Hcl Ulget Teikoku Capsule 
 Lonmiel Shionogi Capsule 
Cephalosporin Meiact Meiji Seika Tablet 
Nicotine Nicorette Pfizer Tablet 
Nimesulide Nimedex Novartis Tablet 
2-Hydroxy propyl-β-
cyclodextrin(HPβCD) 
   
Itraconazole Sporanox Janssen Oral and IV solution 
Sulfabutyl ether-β-cyclodextrin 
sodium salt 
   
Voriconazole Vfend Pfizer IV solution 
Ziprasidone Mesylate Geodon Zeldox Pfizer IM solution 




                 Figure 1 Phase diagram showing supercritical fluid region. 
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aqueous solubility, physical and microbiological 
stability and to reduce toxicity of the parent 
CDs. The majority of drugs form apparent 1:1 
complexes with CDs although the formation of 




Amorphization is one of the techniques 
to enhance the dissolution rate and 
bioavailability of poorly water soluble drugs 
(Pasquali and Bettini, 2008). Delivering the 
pharmaceutical active ingredient in the 
amorphous form is very attractive due to the 
potentially large increases in drug solubility, 
dissolution rate, and bioavailability (Baldyga, 
2010). The amorphous form of drugs can have 
as much as a 10-1600 fold higher solubility than 
their crystalline forms (Yasuji, 2008). The 
improvement in dissolution of amorphous 
systems can be attributed to improved wetting 
of the drug, deagglomeration and micellization 
of the drug with hydrophilic polymers and the 
high energy amorphous state of the drug (Ito, 
2006). 
However, the amorphous forms of drugs 
are physically unstable due to their higher 
energy state and may recrystallize over 
pharmaceutically relevant time scales, negating 
any solubility advantage. The most typically 
used approach to stabilize an amorphous 
system is to combine it with pharmaceutically 
acceptable polymers, such as polyvinylprroli-
done, polyvinylpyrrolidone vinyl acetate, 
polyethylene glycol and various hydroxypropyl-
methyl cellulose and polyacrylic acid derivatives 
(Hancock, 1997). Thermodynamically the drug 
has a lower chemical potential when mixed 
with a polymer, resulting in a change of 
crystallization driving force (Yu, 2001). The 
long polymeric chains can sterically hinder the 
association between drug molecules and, 
thereby, inhibit the recrystallization of drug. In 
addition, the interaction between the drug and 
polymer provides an increased energy barrier 
for nucleation and, consequently, enhances the 
physical stability (Hancock and Parks 2000). 
Amorphous drug-polymer systems are 
commonly characterized in terms of physical 
properties such as the glass transition 
temperature (Tg), heat capacity and miscibility. 
Although it is still not completely clear as to 
how the polymer stabilizes. 
The amorphous drug in the mixture, 
drug polymer miscibility is generally considered 
as one of the critical attributes that affect the 
stability of the amorphous systems, which in 
turn is dictated by the thermodynamics of 
mixing (Chokshi et al., 2007). The entropy of 
mixing is always favorable (an increase on 
mixing) providing one driving force facilitating 
mixing. The enthalpic component of the Gibbs 
function of mixing is controlled by the relative 
strength of the cohesive drug - drug, polymer - 
polymer and the drug - intercomponent 
interactions (Konno and Taylor 2006).  
 
CONCLUSION 
Microparticles of the poorly water 
soluble drugs were produced by the 
supercritical antisolvent method and 
simultaneously mixed with pharmaceutical 
excipients in a single step to prevent the drug 
agglomeration of drug particles. In the third 
approach cyclodextrins (CDs) were used as 
pharmaceutical solubilizers and inclusion 
complexes of drugs with β-CD 
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